Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
oral contraceptive |
| gptkbp:activeIngredient |
gptkb:levonorgestrel
gptkb:ethinyl_estradiol |
| gptkbp:alternativeName |
Alesse 21
Alesse 28 |
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:class |
oral contraceptive
|
| gptkbp:contains |
0.02 mg ethinyl estradiol
0.1 mg levonorgestrel |
| gptkbp:contraindication |
gptkb:liver_disease
history of thromboembolic disorders known or suspected pregnancy |
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alesse
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketedIn |
gptkb:Canada
gptkb:United_States |
| gptkbp:mechanismOfAction |
inhibits ovulation
alters endometrial lining thickens cervical mucus |
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache breast tenderness irregular bleeding |
| gptkbp:usedFor |
birth control
|
| gptkbp:bfsParent |
gptkb:ethinyl_estradiol
|
| gptkbp:bfsLayer |
7
|